ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Perseus Proteomics, Inc. ?
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Poor long term growth as Net Sales has grown by an annual rate of 18.73% and Operating profit at -34.81% over the last 5 years
3
Positive results in Jun 25
- NET SALES(HY) At JPY 60.78 MM has Grown at 22.59%
- DEBT-EQUITY RATIO (HY) Lowest at -119.8 %
- DEBTORS TURNOVER RATIO(HY) Highest at 5.59%
4
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -66.09%, its profits have risen by 5.6%
5
Below par performance in long term as well as near term
- Along with generating -66.09% returns in the last 1 year, the stock has also underperformed Japan Nikkei 225 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Perseus Proteomics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Perseus Proteomics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Perseus Proteomics, Inc.
-64.98%
-0.46
70.02%
Japan Nikkei 225
25.38%
1.00
25.76%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
18.73%
EBIT Growth (5y)
-34.81%
EBIT to Interest (avg)
-725.94
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.16
Sales to Capital Employed (avg)
0.06
Tax Ratio
0.27%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.63
EV to EBIT
-5.98
EV to EBITDA
-6.01
EV to Capital Employed
-21.08
EV to Sales
41.25
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-58.10%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Bearish
Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend15What is working for the Company
NET SALES(HY)
At JPY 60.78 MM has Grown at 22.59%
DEBT-EQUITY RATIO
(HY)
Lowest at -119.8 %
DEBTORS TURNOVER RATIO(HY)
Highest at 5.59%
PRE-TAX PROFIT(Q)
Highest at JPY -171.49 MM
NET PROFIT(Q)
Highest at JPY -171.97 MM
EPS(Q)
Highest at JPY -11.94
-3What is not working for the Company
NET SALES(Q)
At JPY 23.47 MM has Fallen at -22%
Here's what is working for Perseus Proteomics, Inc.
Debt-Equity Ratio
Lowest at -119.8 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Pre-Tax Profit
Highest at JPY -171.49 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (JPY MM)
Net Profit
Highest at JPY -171.97 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (JPY MM)
EPS
Highest at JPY -11.94
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (JPY)
Debtors Turnover Ratio
Highest at 5.59%
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Here's what is not working for Perseus Proteomics, Inc.
Net Sales
At JPY 23.47 MM has Fallen at -22%
over average net sales of the previous four periods of JPY 30.09 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (JPY MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
